TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01371630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study: NCT00620256

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AL-37807 ophthalmic solution vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Study: NCT01371630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT01571986

Intervention type: PROCEDURE
Intervention: Non-invasive ventilation
Description: Non-invasive ventilation
Study: NCT00620256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Study: NCT03781895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: • Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: • Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)
Study: NCT03745924

Intervention type: DRUG
Intervention: Nonacog beta pegol
Description: Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
Study: NCT03781895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: • Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: • Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)
Study: NCT00804154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Resiniferatoxin
Description: phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
Study: NCT03705585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivotif Typhoid Oral Vaccine
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivotif Typhoid Oral Vaccine
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxchora
Description: One dose. Approximately 100 mL of cool or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxchora
Description: One dose. Approximately 100 mL of cool or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
Study: NCT03152773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Heart guidewire catheterization
Description: to conduct left and right heart guidewire catheterization using real-time MRI fluoroscopy in human research subjects already undergoing medically necessary left and right heart catheterization. We will use only passive MRI-compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
Study: NCT03770325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Purified berberine (500 mg orally twice a day) in tablets for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, prepared with the same appearance, for 12 weeks
Study: NCT03914547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDCHiP
Description: REDCHiP includes 10 telehealth sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ATTN
Description: Provides a similar attention control. ATTN includes 10 telehealth sessions.
Study: NCT00223171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen blockade + radiation therapy
Description: Androgen blockade + radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen blockade + radiation therapy
Description: Androgen blockade + radiation therapy
Study: NCT02811432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
Study: NCT04605874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Package Quantity (cigarillos)
Description: After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
Study: NCT02429219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Irrigation with Ethanol
Description: Saline Irrigation with Ethanol (alcohol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Irrigation with Ethanol
Description: Saline Irrigation with Ethanol (alcohol)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral resection of the prostate
Description: transurethral electro-resection of the prostate (TURP)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photoselective vaporisation of the prostate
Description: photoselective laser-vaporisation of the prostate (PVP)
Study: NCT04404036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSonic Device
Description: A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
Study: NCT04054869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-mechanically correct manual therapy at the cervical atlanto-axial joints
Description: Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-mechanically correct manual therapy at the cervical atlanto-axial joints
Description: Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints
Description: Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints
Description: Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
Study: NCT02982434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmaceutical composition containing botulinum toxin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Study: NCT04221737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APRV. General Electric Healthcare Engstrom ventilator system
Description: APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional. General Electric Healthcare Engstrom ventilator system
Description: Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
Study: NCT02767089

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
Study: NCT03636997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Draining seton
Description: Number 1 silk suture was passed through the fistula track and tied as loose seton

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rerouting of track
Description: The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
Study: NCT01233895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
Study: NCT02834013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT02767089

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
Study: NCT03023410

Intervention type: PROCEDURE
Intervention: VERASENSE
Description: Sensor-Assisted Revision TKA

Intervention type: PROCEDURE
Intervention: VERASENSE
Description: Sensor-Assisted Revision TKA
Study: NCT03418038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV or PO
Study: NCT02834013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04159870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin pills 400 mg x 3/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norlfloxacin 400 mg 1 pill/day
Study: NCT04774848

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Jet Ventilator
Description: HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Jet Ventilator
Description: HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
Study: NCT01675271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual exercise
Description: individual exercise and dietary prescription

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general exercise
Description: general exercise counselling
Study: NCT03440021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Novel selective alpha2c adrenoceptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Novel selective alpha2c adrenoceptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in appearance to experimental drug, not psycho-active
Study: NCT02373215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCL ER
Description: Nalbuphine HCL extended release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCL ER
Description: Nalbuphine HCL extended release tablet
Study: NCT03418038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study: NCT01140997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: sc, qw, for 48 weeks.